“Dermatology Drugs Market by Therapeutic Area Segments (Atopic Dermatitis, Psoriasis, Acne, Rosacea), Acne Drug Types (Doxycycline, Absorica, Clindamycin, Myorisan, Aczone, Epiduo) Marketed Therapies (Biologics, Oral Drugs, Topical Drugs), by Approves Treatments (Etanercept (Enbrel), Infliximab (Remicade), Adalimumab (Humira), Ustekinumab (Stelara), Secukinumab (Cosentyx), Ixekizumab (Taltz), Golimumab (Simponi), Brodalumab (Siliq), Guselkamab (Tremfya) and Others) and by Regions (North America, Europe, Asia Pacific, Latin America and Middle East & Africa) – Global Forecasts to 2022″- Report by Polaris Market Research
The Global Dermatology Drugs Market was valued at USD 21.32 billion in 2017 as reported by Polaris Market Research. The market is primed to exhibit strong commercial opportunity driven by psoriasis, atopic dermatitis, and aesthetic dermatology indications. The market expansion in dermatology is fueled by the addition of improved formulations of approved treatments in acne and rosacea and the approval of several biologics in psoriasis in recent times. The dermatology is a large but fragmented market opportunity and there remains the significant unmet need for safer and cost-effective treatment options.
Request For Sample Of This Research Report @ https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market-/request-for-free-sample
The psoriasis market remains the largest and the most promising segment within the broader dermatology category. The psoriasis market is poised to increase from USD 4.08 billion in 2017 to over USD 4.86 billion in 2022 driven by increased penetration of anti-TNFs and the recent market launch of a wave of next-generation biologics led by interleukin (IL-17) class.
There remains significant unmet need to treat moderate to severe atopic dermatitis due to limited effective and long-term therapeutic options. Acne infected population is substantially large and Polaris estimates the market to reach USD 8.47 billion by 2022. Atopic Dermatitis was the largest therapeutic area segment in 2017. And, Polaris estimates that this segment is projected to increase at a CAGR of 3.9% from 2018 to 2022.
Polaris Market Research estimates the acne at over USD 6.8 billion in 2017. The key prescription treatments for acne include topical retinoids, topical and oral antimicrobials, and oral isotretinoin. The non-prescription market for acne is more attractive commercially and is expected to almost double the size of the prescription market by 2022. Topical therapies dominate acne treatment and hold the majority of the market share. Several promising drugs are currently in clinical development in the treatment of acne. Key among them includes Foamix’s FMX-101, the first topical minocycline that demonstrated positive results in the Phase III study. Dermira’s DRM01 remains the first topical sebum inhibitor which demonstrated improved efficacy in Phase II trials. The Phase III study results in adult and adolescent acne patients are expected to read out in 2018.
Geographically, the U.S. remained the single largest market followed by Europe and Japan. The largest market size of the U.S. is attributable to rising adoption of high-priced biologics. The penetration of biologics in the U.S. for dermatological indication especially in psoriasis is still below 10% and the market continues to remain underpenetrated.
Browse Full Research Report with Table of Content @ https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market-/
Polaris Market Research has modelled forecast market sales of Dermatology drugs from 2016-2022. The key therapeutic segments which have been investigated in the global market from 2016-2022 are:
- Market Analysis by Key Therapeutic Indications
- Market Analysis by Leading and Emerging Approved Treatment Types
- Market Analysis by Marketed Drugs
- Market Analysis by Geographic Regions
Therapeutic Area Segments
- Atopic Dermatitis
Acne Drug Segments
Marketed Therapies Segments
- Oral Drugs
- Topical Drugs
Approved Treatments Segments
- Etanercept (Enbrel)
- Infliximab (Remicade)
- Adalimumab (Humira)
- Ustekinumab (Stelara)
- Secukinumab (Cosentyx)
- Lxekizumab (Taltz)
- Golimumab (Simponi)
- Brodalumab (Siliq)
- Guselkamab (Tremfya)
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. We provide unmatched quality of offerings to our clients present globally. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities.
We mainly focus on aiding our customers with substantial competitive intelligence, helping them to secure a competitive advantage in the market and accomplish sustainable growth in different market domains. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers. Through dedicated qualitative and quantitative primary and secondary market research and consulting assignments, we adeptly formulate competitive strategies to address business challenges for our clients through analyzing market trends and emerging technologies.
Company Name: Polaris Market Research and Consulting
Contact Person: Mr.Neel
Email: Send Email
Address:30 Wall Street 8th Floor New York City, NY 10005 United States
City: New York
State: New York 10005
Country: United States